SCHEMBL428943

SCHEMBL428943

[CH2]c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 17/20 0.62
CA9 Q16790 13/20 0.62
CA12 O43570 12/20 0.62
CA1 P00915 14/20 0.59
CA5A P35218 8/20 0.59
CA7 P43166 8/20 0.59
CA5B Q9Y2D0 8/20 0.59
CA6 P23280 6/20 0.59
CA4 P22748 6/20 0.59
CA14 Q9ULX7 6/20 0.59
CA13 Q8N1Q1 3/20 0.59
USP2 O75604 1/20 0.59
TSHR P16473 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
AGO2 Q9UKV8 1/20 0.59
CA3 P07451 3/20 0.56
PLA2G7 Q13093 1/20 0.55
ALDH1A1 P00352 1/20 0.54
HTT P42858 1/20 0.54
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202948 0.85 CA2 (0.81) CA2CA9CA12CA1CA5A
SCHEMBL216845 0.77 CA2 (0.64) CA2CA9CA12CA1CA5A
SCHEMBL10493509 0.77 CA2 (0.68) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL11751516 0.76 CA2 (0.90) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL2746422 0.76 CA2 (0.90) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL30659052 0.74 CA2 (1.00) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL31544839 0.74 CA2 (1.00) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL2798899 0.74 CA2 (1.00) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL740 0.74 CA2 (1.00) CA2CA9CA12CA1CA5A
SCHEMBL1805283 0.74 CA2 (0.65) CA2CA9CA12CA1CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066027-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2024-02-29 US claimed
EP-4255904-A2 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2023-10-11 EP claimed
WO-2022117882-A2 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2022-06-09 WO claimed
WO-2021062089-A1 XANTHINE CB1 INHIBITORS GOLDFINCH BIO, INC. (US) 2021-04-01 WO claimed
EP-2791142-B1 COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS US HEALTH (US) 2019-07-03 EP claimed
US-20190053492-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES BAYER CROPSCIENCE AG (DE) 2019-02-21 US claimed
EP-3429997-A1 N-(CYANOBENZYL)-6-(CYCLOPROPYL-CARBONYLAMINO)-4-(PHENYL)-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES AND PLANT PROTECTION AGENTS Bayer CropScience Aktiengesellschaft (DE) 2019-01-23 EP claimed
CN-109071444-A N- (cyanobenzyl) -6- (cyclopropyl-carbonylamino) -4- (phenyl) -pyridine-2-carboxamide derivatives and related compounds as pesticides and plant protection agents 拜耳作物科学股份公司 2018-12-21 CN claimed
CN-108697719-A Modulators of extracellular 5' -nucleotidase and uses thereof 艾库斯生物科学有限公司 2018-10-23 CN claimed
WO-2018140630-A1 AUTOPHAGY INDUCERS FOR TREATMENT OF CNS CONDITIONS NORTHWESTERN UNIVERSITY (US) 2018-08-02 WO claimed
EP-0911030-B1 Antimicrobial composition comprising a vinyyl pyrrolidinon derivative and a carbapenem antibiotic or a beta-lactamase inhibitor BASILEA PHARMACEUTICA AG (CH) 2005-04-13 EP claimed
US-6479492-B1 TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT ELAN PHARMACEUTICALS, INC. 2002-11-12 US claimed
US-6369070-B1 Methods for inhibiting mrp1 ELI LILLY AND COMPANY 2002-04-09 US claimed
EP-1067928-A4 METHODS FOR INHIBITING MRP1 LILLY CO ELI (US) 2001-11-14 EP claimed
CN-1304306-A Method for inhibiting MRP1 LILLY CO ELI (US) 2001-07-18 CN claimed
EP-1067928-A1 METHODS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-01-17 EP claimed
WO-1999051228-A1 METHODS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 1999-10-14 WO claimed
EP-0911030-A2 Antimicrobial composition comprising a vinyyl pyrrolidinon derivative and a carbapenem antibiotic or a beta-lactamase inhibitor F.HOFFMANN-LA ROCHE AG (CH) 1999-04-28 EP claimed
EP-0356454-B1 CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN THE UPJOHN COMPANY (US) 1992-06-17 EP claimed
US-4025622-A ANTIBACTERIAL Ogura, Haruo (JA) 1977-05-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190053492-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES CHRM1, CHRM2, ACHE CA2 1370/4885CA9 3063/4885CA12 4356/4885
US-20240066027-A1 NOVEL PAR-2 INHIBITORS F2RL1, F2R, F2RL3 CA2 2401/4885CA9 3574/4885CA12 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.